Approval Background

On February 9, 1999, the European Medicines Agency (EMA) granted final approval for leflunomide as a treatment for rheumatoid arthritis. The approval was driven by the growing need for an orally administered immunomodulator, in contrast to the injection‑based disease‑modifying antirheumatic drugs (DMARDs) that dominated the market.

Clinical Evidence

Clinical trials demonstrated that leflunomide provided significant efficacy and a manageable safety profile in patients with rheumatoid arthritis. The most common adverse event was elevation of liver enzymes, which could be controlled with appropriate monitoring.

Competitive Positioning

Leflunomide is a dihydroorotate dehydrogenase (DHODH) inhibitor, offering a mechanism of action distinct from existing agents such as methotrexate. As the first oral DHODH inhibitor, it occupies a differentiated position in the market.

Reimbursement and Market Entry

Health authorities across Europe evaluated pricing and cost‑effectiveness to determine reimbursement status, initially granting limited coverage. Over the longer term, the drug is expected to improve patient convenience and reduce overall treatment costs.

Long‑Term Impact

Since approval, leflunomide has been utilized throughout Europe and has inspired the development of additional oral DMARDs. This has expanded the therapeutic paradigm for rheumatoid arthritis and influenced the research direction of pharmaceutical companies.